The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]
Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
Dublin, Ireland, 14th April 2016: Afimmune is today presenting a late-breaking news abstract at the annual meeting of the EASL International Liver Congress in Barcelona, Spain […]
Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]
Dublin, Ireland, November 9th, 2015 – Afimmune, a privately held biopharmaceutical company, announced today that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 […]
Afimmune today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis (NASH). DS102 […]
